SK12682000A3 - Proteíny interagujúce s kaspázou-8, izolovaná dna, vektor obsahujúci dna sekvenciu, eukaryotická a prokaryotická bunka, spôsob ich výroby a ich použitie - Google Patents

Proteíny interagujúce s kaspázou-8, izolovaná dna, vektor obsahujúci dna sekvenciu, eukaryotická a prokaryotická bunka, spôsob ich výroby a ich použitie Download PDF

Info

Publication number
SK12682000A3
SK12682000A3 SK1268-2000A SK12682000A SK12682000A3 SK 12682000 A3 SK12682000 A3 SK 12682000A3 SK 12682000 A SK12682000 A SK 12682000A SK 12682000 A3 SK12682000 A3 SK 12682000A3
Authority
SK
Slovakia
Prior art keywords
caspase
protein
cell
leu
interacting
Prior art date
Application number
SK1268-2000A
Other languages
English (en)
Slovak (sk)
Inventor
David Wallach
Marcus Schuchmann
Tanya Goncharov
Original Assignee
Yeda Research And Development Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12772198A external-priority patent/IL127721A0/xx
Application filed by Yeda Research And Development Company Limited filed Critical Yeda Research And Development Company Limited
Publication of SK12682000A3 publication Critical patent/SK12682000A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01033—N-Acetylglucosamine deacetylase (3.5.1.33)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
SK1268-2000A 1998-12-24 1999-12-23 Proteíny interagujúce s kaspázou-8, izolovaná dna, vektor obsahujúci dna sekvenciu, eukaryotická a prokaryotická bunka, spôsob ich výroby a ich použitie SK12682000A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12772198A IL127721A0 (en) 1998-12-24 1998-12-24 Caspase-8 interacting proteins
IL13210599A IL132105A0 (en) 1998-12-24 1999-09-28 Caspase-8 interacting proteins
PCT/IL1999/000698 WO2000039160A2 (en) 1998-12-24 1999-12-23 Caspase-8 interacting proteins

Publications (1)

Publication Number Publication Date
SK12682000A3 true SK12682000A3 (sk) 2001-03-12

Family

ID=26323761

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1268-2000A SK12682000A3 (sk) 1998-12-24 1999-12-23 Proteíny interagujúce s kaspázou-8, izolovaná dna, vektor obsahujúci dna sekvenciu, eukaryotická a prokaryotická bunka, spôsob ich výroby a ich použitie

Country Status (20)

Country Link
US (3) US6762283B1 (ko)
EP (1) EP1058691A1 (ko)
JP (1) JP2002536965A (ko)
KR (2) KR100646074B1 (ko)
CN (2) CN1223608C (ko)
AR (1) AR029321A1 (ko)
AU (1) AU780585B2 (ko)
BG (2) BG65375B1 (ko)
BR (1) BR9909252A (ko)
CA (1) CA2321672A1 (ko)
EA (2) EA005853B1 (ko)
EE (1) EE200000487A (ko)
HK (1) HK1037197A1 (ko)
HU (1) HUP0100671A3 (ko)
IL (3) IL132105A0 (ko)
NO (1) NO20004167L (ko)
NZ (1) NZ506477A (ko)
PL (1) PL350181A1 (ko)
SK (1) SK12682000A3 (ko)
WO (1) WO2000039160A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002103A (es) * 2001-09-04 2004-06-07 Yeda Res & Dev Una proteina de union a caspasa-8, su preparacion y uso.
US20040072770A1 (en) * 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8
IL158599A0 (en) * 2003-10-26 2004-05-12 Yeda Res & Dev Methods of modulating hematopoiesis
JP5513130B2 (ja) * 2007-02-23 2014-06-04 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物
US8809002B2 (en) * 2008-07-10 2014-08-19 Dana-Farber Cancer Institute, Inc. MUC1, caspase-8, and DED-containing proteins
JP6710680B2 (ja) 2014-09-04 2020-06-17 メモリアル スローン ケタリング キャンサー センター ヘモグロビン異常症を処置するためのグロビン遺伝子療法
CN104694485A (zh) * 2015-02-13 2015-06-10 广西壮族自治区兽医研究所 Z-ietd-fmk在提高prrsv体外培养滴度方面的应用及其方法
CN106146665B (zh) * 2016-08-31 2019-08-09 中国农业科学院植物保护研究所 一种用于制备针对甜菜夜蛾caspase-5大亚基的抗体的方法
JP2020510097A (ja) * 2017-03-16 2020-04-02 イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． リンカーユニット及びリンカーユニットを含む分子構築物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
JPH0625292A (ja) * 1990-10-31 1994-02-01 Mitsui Toatsu Chem Inc タンパク質及びその遺伝子
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5364503A (en) 1992-02-20 1994-11-15 Macmillan Bloedel Limited Nitric oxide treatment for ozone bleaching
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
IL104355A (en) * 1993-01-10 2006-08-20 Yeda Res & Dev Tnf receptor promoter
IL109633A (en) * 1994-05-11 2005-05-17 Yeda Res & Dev Tnf receptor promoter
JP2002514903A (ja) * 1996-06-17 2002-05-21 ジンザイム コーポレイション 新規のヒト第１６染色体遺伝子、組成物、それを作製および使用する方法
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
JP2003500002A (ja) * 1998-05-29 2003-01-07 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトヒドロラーゼ相同体：ｎ−末端アスパラギンアミドヒドロラーゼ、グリコシルヒドロラーゼ、グルコヒドロラーゼ、ビオチニダーゼ及びｎ−アセチルグルコサミン６−ｐデアセチラーゼ
US6326354B1 (en) * 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
CA2350415A1 (en) * 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
EP1002900A1 (de) 1998-11-18 2000-05-24 SP Beton GmbH & Co. KG Verkehrsflächen-Bodenbelag mit Bodenbelagelementen aus Kunststeinmaterial

Also Published As

Publication number Publication date
IL132105A0 (en) 2001-03-19
KR100646075B1 (ko) 2006-11-15
BG65375B1 (bg) 2008-04-30
PL350181A1 (en) 2002-11-18
EE200000487A (et) 2002-02-15
KR20010041250A (ko) 2001-05-15
EP1058691A1 (en) 2000-12-13
NO20004167D0 (no) 2000-08-21
US6762283B1 (en) 2004-07-13
CN1298411A (zh) 2001-06-06
IL178921A0 (en) 2007-03-08
WO2000039160A2 (en) 2000-07-06
EA007273B1 (ru) 2006-08-25
NO20004167L (no) 2000-10-19
KR20060090770A (ko) 2006-08-16
WO2000039160A3 (ko) 2001-08-23
AU1795000A (en) 2000-07-31
CN1603342A (zh) 2005-04-06
EA005853B1 (ru) 2005-06-30
US7339047B2 (en) 2008-03-04
HUP0100671A3 (en) 2006-04-28
NZ506477A (en) 2003-08-29
HUP0100671A2 (hu) 2001-06-28
BR9909252A (pt) 2000-11-28
AU780585B2 (en) 2005-04-07
JP2002536965A (ja) 2002-11-05
US20040229260A1 (en) 2004-11-18
BG109904A (bg) 2008-01-31
IL138025A (en) 2007-08-19
EA200401390A1 (ru) 2005-02-24
CA2321672A1 (en) 2000-07-06
EA200000875A1 (ru) 2001-10-22
HK1037197A1 (en) 2002-02-01
KR100646074B1 (ko) 2006-11-13
US20080139476A1 (en) 2008-06-12
AR029321A1 (es) 2003-06-25
BG104707A (en) 2001-04-30
CN1223608C (zh) 2005-10-19

Similar Documents

Publication Publication Date Title
US20070166787A1 (en) Modulators of regulatory proteins
US20080139476A1 (en) Caspase-8 interacting proteins
JP3787355B2 (ja) Ｆａｓ／ａｐｏ１受容体機能のモジュレーター
EP0813419B1 (en) Modulators of regulatory proteins
US20080254028A1 (en) Caspase-8 binding protein, its preparation and use
IL109632A (en) Modulators of the function of tnf receptors
SK117599A3 (en) Dna sequence, a vector containing it, a host cell, isoform of g1 protein, method for producing isoform of g1 protein, pharmaceutical composition containing it and its use
AU2004240157B2 (en) Caspase-8 interacting proteins
CZ20003098A3 (cs) Proteiny interagující s kaspázou-8
MXPA00008260A (en) Caspase-8 interactingproteins
US7108999B1 (en) Modulators of the function of FAS/AP01 receptors
AU5133296A (en) Modulators of regulatory proteins
AU2002324325A1 (en) A caspase- 8 binding protein, its preparation and use
IL112692A (en) ANTIBODIES TO PROTEIN WHICH BINDS TO Fas-R
AU5834599A (en) Modulators of regulatory proteins

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure